3SOF

Profile :



Warner Chilcott plc
Unit 19 Ardee Business Park
Hale Street
Ardee,  
Ireland - Map
Phone: 353 41 685 6983
Web Site: http://www.warnerchilcott.com

DETAILS  
Index Membership: Nasdaq 100
Sector: Healthcare
Industry: Drug Manufacturers - Other
Full Time Employees: 1,115


BUSINESS SUMMARY  
Warner Chilcott Limited, a specialty pharmaceutical company, engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products in women's healthcare and dermatology segments primarily in the United States. The company offers various women healthcare products, including LOESTRIN 24 FE and FEMCON FE as oral contraceptives; FEMHRT 1/5 and .5/2.5 for oral treatment of moderate to severe vasomotor symptoms and urogenital symptoms associated with menopause; and ESTRACE cream to treat vaginal and vulvar atrophy. It also offers various dermatology products, such as TACLONEX and DOVONEX for the topical treatment of psoriasis; and DORYX, an oral adjunctive therapy for severe acne. In addition, its products under development include WC3016 and WC3026, the Phase III clinical trial completed products for low-dose oral contraceptive; WC2055, a Phase II clinical trials completed product for the treatment of acne; WC3018, a Phase II clinical trials product for the treatment of acne and other inflammatory skin conditions; LEO 80-185 for psoriasis of the scalp; and LEO 80-190, a Phase III clinical trial product for the treatment of psoriasis. Further, the company's products under development comprise TD1414, a Phase II clinical trial product for skin infections; WC3027 for the treatment of inflammatory skin conditions; WC3035 for the treatment of acne and rosacea; and WC3036 and WC3043 for the treatment of erectile dysfunction. Warner Chilcott's principal customers include wholesale pharmaceutical distributors, and retail drug and grocery store chains. It has license and supply agreement with LEO Pharma A/S. The company was founded in 1968 and is headquartered in Rockaway, New Jersey.

This NASDAQ 100 stock has been on a run...
Nice up trend. New highs bring new highs!
Let's watch and see what else may take place.
Would like to see + volume

52wk Range: 9.24 - 27.99
Volume: 1,247,256
Avg Vol (3m): 1,694,750
Market Cap: 6.97B
P/E (ttm): 17.02
EPS (ttm): 1.63


Technicals
Last Price Quote is:
7.21%above 13-day MA
17.37%above 50-day MA
RS Rating: 93 

Fundamentals
Key Data:
Market Cap (M): $6,781.61 
P/E Ratio: 16.60 
PEG Ratio: 1.42991 
Next Earnings: 02/19/2010
Last Analyst Rating: Buy